Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics.
Nagy-Szakal, Dorottya, Barupal, Dinesh K, Lee, Bohyun et al. · Scientific reports · 2018 · DOI
Quick Summary
Researchers studied blood and gut bacteria samples from 50 people with ME/CFS and 50 healthy people to find biological markers of the disease. They found that people with ME/CFS have abnormal levels of certain substances in their blood called metabolites, particularly a fatty molecule called ceramide in those who also have irritable bowel syndrome. When scientists combined information about both blood metabolites and gut bacteria, they could identify ME/CFS patients more accurately than using either test alone.
Why It Matters
This study provides objective biological markers that could eventually lead to better diagnostic tests for ME/CFS, potentially ending the long diagnostic odyssey many patients experience. The discovery of distinct metabolic signatures in ME/CFS subgroups (particularly those with IBS) suggests that personalized treatment approaches may be possible. These findings strengthen evidence that ME/CFS has measurable biological underpinnings rather than being primarily psychological.
Observed Findings
Confirmed dysregulation of plasma choline, carnitine, and complex lipid metabolites in ME/CFS patients compared to healthy controls.
Elevated ceramide levels specifically in ME/CFS patients who also have irritable bowel syndrome.
Fecal bacterial composition differs between ME/CFS patients and healthy controls.
Combined metabolomic and metagenomic analysis achieved cross-validated AUC = 0.836 for ME/CFS identification.
Integration of multiple biological data types (metabolites and gut microbiota) provides stronger diagnostic potential than either biomarker class alone.
ME/CFS involves dysregulation of lipid metabolism and energy metabolism pathways (carnitine and choline), suggesting mitochondrial or energy-processing dysfunction.
ME/CFS with comorbid IBS represents a distinct metabolic phenotype characterized by elevated ceramide, suggesting different underlying mechanisms in this subgroup.
These metabolomic and metagenomic signatures could form the basis for future diagnostic tests and targeted therapeutic interventions.
Remaining Questions
What This Study Does Not Prove
This study does not prove that the identified metabolic changes cause ME/CFS symptoms—they may be consequences of the disease rather than causes. The findings cannot be generalized to all ME/CFS patients since the study involved only 50 patients and did not explore the full diversity of ME/CFS presentations. The study also does not establish whether these biomarkers can be used for routine clinical diagnosis without validation in larger, prospective populations.